Access Bio, Inc. (KOSDAQ:950130)

South Korea · Delayed Price · Currency is KRW

1,869.00

-42.00 (-2.20%)

Nov 3, 2026, 12:35 PM KST

Market Cap	65.74B -52.1%
Revenue (ttm)	23.54B -68.3%
Net Income	-110.91B
EPS	-3,149.61
Shares Out	35.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	823.00 (44.03%)
Ex-Dividend Date	n/a

Volume	18,780
Open	1,944.00
Previous Close	1,911.00
Day's Range	1,868.00 - 1,945.00
52-Week Range	1,777.00 - 4,705.00
Beta	0.47
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Access Bio

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; a... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2002

Employees 101

Stock Exchange KOSDAQ

Ticker Symbol 950130

Full Company Profile

Financial Performance

In 2025, Access Bio's revenue was 31.26 billion, a decrease of -72.21% compared to the previous year's 112.46 billion. Losses were -82.12 billion, 23525.9% more than in 2024.

Financial Statements